

## **PROLIGHT RECEIVES NOTICE OF INTENTION TO GRANT IN EUROPE FOR THIRD PSYROS™ PATENT**

**Prolight Diagnostics announces today that the European Patent Office (EPO) has issued a Notice of Intention to Grant for the company's third patent application related to its proprietary Psyros™ single-molecule-counting technology. This is the third Psyros™ patent to be granted by the EPO in 2025.**

"We are delighted to receive confirmation that the EPO intends to grant another patent for our Psyros™ technology", said Ulf Bladin, CEO of Prolight Diagnostics. "The pace at which our patents are being granted highlights the uniqueness of the technology and our strong freedom-to-operate."

The Psyros™ technology uses photoactive reporter molecules to permanently bleach dark spots in a fluorescent layer, with each spot representing a single molecule binding event. This patent application (EP application number 23 716 913.1) protects a novel embodiment of the technology that uses light of two different wavelengths to generate the dark spots. Final formalities are now underway before the patent is officially granted under number EP 4 496 995.

Prolight currently holds six patent families related to the Psyros™ platform. The first three families are in the national or regional phases across territories worldwide. Families four and five are in the PCT phase and will enter the national/regional phases later this year. The sixth family is a priority application filed in the UK.

Earlier this year, patents from the first two families were granted in Europe and have since been validated in 17 European countries. Additionally, the first family patent was granted in Japan, further strengthening Prolight's global intellectual property position.

**For further information, please contact:**

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

**About Us**

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

## **Attachments**

**Prolight receives Notice of Intention to Grant in Europe for third Psyros™ patent**